Thus, hepatocyte‐directed IL‐1 inhibition could be an adjunctive strategy to weight loss in obese patients to improve hepatic insulin resistance, mitochondrial dysfunction, and ultimately the risk to develop overt type 2 diabetes. Here, IL1B is linked to type 2 diabetes mellitus.